title: Safety and tolerability of 13-valent pneumococcal conjugate vaccine in healthy Chinese adults, children and infants.
abstract: Pneumococcal disease is a global problem, including in China. The objective of this study was to provide safety data for single-dose 13-valent pneumococcal conjugate vaccine (PCV13) in Chinese subjects, needed to begin a phase III safety and immunogenicity study in Chinese infants.
  
  
  
  Healthy Chinese adults (18-55 years), children (3-5 years), and infants (42-98 days) received a single dose of PCV13 in this open-label safety study. Local reactions and systemic events were collected for 7 days via an electronic diary; adverse events were recorded for 1 month after vaccination.
  
  
  
  All 72 (24 per group) screened subjects (58.3% males; mean ± standard deviation [SD] age: 43.3 ± 9.1 years [adults], 4.5 ± 0.7 years [children], and 79.6 ± 15.2 days [infants]) were enrolled, received vaccine, and completed the study. The most frequently reported local reactions per group were pain at the injection site (n = 23 adults [95.8%]), tenderness (n = 18 children [75%]), and swelling (n = 6 infants [25%]), none of which were severe. The mean duration of each local reaction was ⩽2.0 days in infants and ⩽2.4 days in children but in adults was 3.3 days for pain at the injection site and 9 days each for redness and swelling. Systemic events in adults were muscle pain (n = 5), fatigue (n = 3), and headache and joint pain (n = 1 each). One child and seven infants had disturbed sleep (increased or decreased). One adult and one child had mild fever (37.7-38.5°C, as per China Food and Drug Administration guidelines). No subject used antipyretic medication. One adverse event (bronchopneumonia in an infant) was reported, which was serious, severe, and unrelated to vaccination. There were no deaths.
  
  
  
  A single dose of PCV13 was safe and well tolerated in healthy Chinese adults, children, and infants. This study provided the safety data to enable a phase III safety and immunogenicity registration trial in Chinese infants to proceed.
authors.affiliation: Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention 172 Jiangsu Road, Nanjing, Jiangsu Province, 210009, China.
authors.forename: Fengcai
authors.initials: F
authors.lastname: Zhu
authors.affiliation: Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P.R. China.
authors.forename: Yuemei
authors.initials: Y
authors.lastname: Hu
authors.affiliation: Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, P.R. China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Liang
authors.affiliation: Vaccine Clinical Research, Pfizer Inc, Collegeville, PA, USA.
authors.forename: Mariano
authors.initials: M
authors.lastname: Young
authors.affiliation: Vaccine Clinical Research, Pfizer Inc, Shanghai, P.R. China.
authors.forename: Xin
authors.initials: X
authors.lastname: Zhou
authors.affiliation: Vaccine Clinical Research, Pfizer Inc, Shanghai, P.R. China.
authors.forename: Zhangjing
authors.initials: Z
authors.lastname: Chen
authors.affiliation: Vaccine Clinical Research, Pfizer Inc, Collegeville, PA, USA.
authors.forename: John Z
authors.initials: JZ
authors.lastname: Liang
authors.affiliation: Vaccine Clinical Research, Pfizer Inc, Pearl River, NY, USA.
authors.forename: William C
authors.initials: WC
authors.lastname: Gruber
authors.affiliation: Vaccine Clinical Research, Pfizer Inc, Pearl River, NY, USA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Scott
keywords: 13-valent pneumococcal conjugate vaccine; pneumococcal infections; safety